FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
DRREDDY
4,639
+111.55 (2.46%)
Updated 03:29 04/08 IST
DRREDDY Buy or Sell - FrontPage Forums
3 Users have submitted 3 trade ideas of Rs. 674,925.75 for DRREDDY
Disclaimer33% Bullish
67% Bearish
DRREDDY Buy or Sell - Brokerage Reports
No. of reports in last year
15
No. of analysts
7
Average Consensus Forecast
3452.8
Consensus Potential
-33.85%
DRREDDY Ratings
Long term DRREDDY rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
4.5/5 (11 Ratings)
Find answers to all your questions on live DRREDDY message board: Is DRREDDY buy or sell? Should I buy DRREDDY shares? Why are DRREDDY shares falling? Should I invest in DRREDDY stock?
- Home
- DRREDDY Forum
DRREDDY Share Price Discussion
N
Reputation: 4,641 • Today 10:38 AM
Hold Dr. Reddy's; target of Rs 4550: Emkay Global Financial
Emkay Global Financial recommended hold rating on Dr. Reddy's with a target price of Rs 4550 in its research report dated July 29, 2020.
Emkay Global Financial recommended hold rating on Dr. Reddy's with a target price of Rs 4550 in its research report dated July 29, 2020.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Today 10:03 AM
Coronavirus treatment | Sun Pharma launches Favipiravir at Rs 35 per tablet
Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease, the company said.
Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease, the company said.
Moneycontrol
Like
Reply
S
Reputation: 1,495 • Today 3:21 AM
Like
Reply (1)
Latest replies
cancel the order as buy price above @166 not yet triggered
N
Reputation: 4,641 • Today 1:43 AM
Neutral Dr Reddy’s Labs; target of Rs 4600: Motilal Oswal
Motilal Oswal recommended Neutral rating on Dr Reddy’s Labs with a target price of Rs 4600 in its research report dated July 30, 2020.
Motilal Oswal recommended Neutral rating on Dr Reddy’s Labs with a target price of Rs 4600 in its research report dated July 30, 2020.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Yesterday 7:38 AM
Hold Dr. Reddy's Laboratories; target of Rs 4326: Prabhudas Lilladher
Prabhudas Lilladher recommended Hold rating on Dr. Reddy's Laboratories with a target price of Rs 4326 in its research report dated July 29, 2020.
Prabhudas Lilladher recommended Hold rating on Dr. Reddy's Laboratories with a target price of Rs 4326 in its research report dated July 29, 2020.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Yesterday 6:48 AM
Accumulat Dr Reddy's Laboratories; target of Rs 4721: Dolat Capital
Dolat Capital recommended accumulat rating on Dr Reddy's Laboratories with a target price of Rs 4721 in its research report dated July 29, 2020.
Dolat Capital recommended accumulat rating on Dr Reddy's Laboratories with a target price of Rs 4721 in its research report dated July 29, 2020.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Yesterday 5:43 AM
Reduce Dr. Reddy’s Labs; target of Rs 3940: HDFC Securities
HDFC Securities recommended reduce rating on Dr. Reddy’s Labs with a target price of Rs 3940 in its research report dated July 30, 2020.
HDFC Securities recommended reduce rating on Dr. Reddy’s Labs with a target price of Rs 3940 in its research report dated July 30, 2020.
Moneycontrol
Like
Reply
N
Reputation: 4,641 • Yesterday 5:23 AM
Buy Dr Reddy's Laboratories; target of Rs 5000: ICICI Direct
ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5000 in its research report dated July 30, 2020.
ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5000 in its research report dated July 30, 2020.
Moneycontrol
Like
Reply
S
Reputation: 8,467 • Aug 2 4:31 AM
List of companies (With Good Q-1 Results)
HDFC Bank
Bharti Airtel
Britania
Sun Pharma
Dr Reddy
Infosys
HCL Tech
Mastek
CDSL
Manappuram
Laurus Lab
#HDFCBANK #BHARTIARTL #BRITANNIA #SUNPHARMA #DRREDDY #INFY #HCLTECH #MASTEK #CDSL #MANAPPURAM #LAURUSLABS
1
Reply
N
Reputation: 4,641 • Jul 31 1:53 AM
Remdesivir shortage to ease in August as existing suppliers boost capacity, new manufacturers enter
Around 8 lakh doses are expected to be available in the country in August as new manufacturers are getting ready to enter the market with their generic versions.
Around 8 lakh doses are expected to be available in the country in August as new manufacturers are getting ready to enter the market with their generic versions.
Moneycontrol
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
DRREDDY Share Price - Technicals
- NewsBotToday 10:38 AMHold Dr. Reddy's; target of Rs 4550: Emkay Global FinancialMoneycontrolNewsBotToday 1:43 AMNeutral Dr Reddy’s Labs; target of Rs 4600: Motilal OswalMoneycontrolNewsBotYesterday 7:38 AMHold Dr. Reddy's Laboratories; target of Rs 4326: Prabhudas LilladherMoneycontrolNewsBotYesterday 6:48 AMAccumulat Dr Reddy's Laboratories; target of Rs 4721: Dolat CapitalMoneycontrolNewsBotYesterday 5:43 AMReduce Dr. Reddy’s Labs; target of Rs 3940: HDFC SecuritiesMoneycontrolNewsBotYesterday 5:23 AMBuy Dr Reddy's Laboratories; target of Rs 5000: ICICI DirectMoneycontrolNewsBotJul 30 4:03 AM
Dr Reddy's share price hits 52-week high post Q1 earningsMoneycontrolNewsBotJul 30 2:28 AM
Trade Spotlight: Dr Reddy’s, IndusInd Bank, Nestle, Maruti and Jubilant Life in focusMoneycontrolNewsBotJul 29 4:33 AM
Dr Reddys Labs Standalone June 2020 Net Sales at Rs 3,244.40 crore, up 29.33% Y-o-YMoneycontrolNewsBotJul 29 4:33 AM
Dr Reddys Labs Consolidated June 2020 Net Sales at Rs 4,426.50 crore, up 14.73% Y-o-YMoneycontrol
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.